急性白血病(ALs)是儿科人群中最常见的癌症。有两种类型的AL:急性淋巴细胞白血病(ALL)和急性髓细胞性白血病(AML)。一些研究表明,肾素血管紧张素系统(RAS)在AL中起作用。RAS信令调制,直接和间接,不同癌症的细胞活性,影响肿瘤细胞和血管生成。我们的综述旨在总结RAS在AL中的作用,并探索通过调节RAS分子治疗这些血液恶性肿瘤的未来前景。数据库包括Pubmed,Scopus,科克伦图书馆,和Scielo进行了搜索,以找到有关ALL和儿科患者中RAS分子的文章。搜索词是“RAS”,“急性白血病”,\"ALL\",“血管紧张素-(1-7)”,“儿科”,\"癌症\",“血管紧张素II”,\"AML\"。在骨髓中,已经发现RAS在血细胞形成中起关键作用,影响几个过程,包括细胞凋亡,细胞增殖,动员,细胞内信号,血管生成,纤维化,和炎症。局部组织RAS通过自分泌和旁分泌作用调节肿瘤生长和转移。RAS主要通过两个分子起作用,血管紧张素II(AngII)和血管紧张素(1-7)[Ang-(1-7)]。虽然AngII促进肿瘤细胞生长并刺激血管生成,Ang-(1-7)抑制肿瘤细胞的增殖和血管生成,提示该分子在ALL中的潜在治疗作用。AL和RAS之间的相互作用揭示了一个复杂的分子网络,可以影响造血和血液癌症的发展。了解这些相互作用可以为针对RAS成分的创新治疗方法铺平道路。
Acute leukemias (ALs) are the most common cancers in pediatric population. There are two types of ALs: acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). Some studies suggest that the Renin Angiotensin System (RAS) has a role in ALs. RAS signaling modulates, directly and indirectly, cellular activity in different cancers, affecting tumor cells and angiogenesis. Our review aimed to summarize the role of RAS in ALs and to explore future perspectives for the treatment of these hematological malignancies by modulating RAS molecules. The database including Pubmed, Scopus, Cochrane Library, and Scielo were searched to find articles about RAS molecules in ALL and in pediatric patients. The search terms were \"RAS\", \"Acute Leukemia\", \"ALL\", \"Angiotensin-(1-7)\", \"Pediatric\", \"Cancer\", \"Angiotensin II\", \"AML\". In the bone marrow, RAS has been found to play a key role in blood cell formation, affecting several processes including apoptosis, cell proliferation, mobilization, intracellular signaling, angiogenesis, fibrosis, and inflammation. Local tissue RAS modulates tumor growth and metastasis through autocrine and paracrine actions. RAS mainly acts via two molecules, Angiotensin II (Ang II) and Angiotensin (1-7) [Ang-(1-7)]. While Ang II promotes tumor cell growth and stimulates angiogenesis, Ang-(1-7) inhibits the proliferation of neoplastic cells and the angiogenesis, suggesting a potential therapeutic role of this molecule in ALL. The interaction between ALs and RAS reveals a complex network of molecules that can affect the hematopoiesis and the development of hematological cancers. Understanding these interactions could pave the way for innovative therapeutic approaches targeting RAS components.